Business Context and Reporting Period
This Form 8-K is filed by Achieve Life Sciences, Inc. (ACHV) on May 7, 2026, with the earliest event reported on that date. The filing primarily addresses corporate governance changes and references the announcement of financial results for the first quarter ended March 31, 2026, which was issued via press release on May 12, 2026.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is referenced but not included in the provided text.
Material Changes and Corporate Events
- Board Appointment: Christopher Martin was appointed as a director on May 11, 2026, pursuant to designation rights granted to Frazier Life Sciences following a private placement.
- Board Resignation: Thomas King resigned as a director and Chairman of the Board, effective June 8, 2026. The resignation was not due to any disagreement with the Company.
- Leadership Transition: Lucian Iancovici, MD, was appointed as the new Chair of the Board, effective June 8, 2026.
- Executive Departure: Jaime Xinos, Chief Commercial Officer, will depart the Company effective May 31, 2026.
Compensation and Governance Details
- Director Compensation: Christopher Martin will receive a pro-rated $40,000 annual retainer for the fiscal year ending December 31, 2026, and a stock option to purchase 47,250 shares of common stock vesting monthly over three years.
- Executive Severance: Jaime Xinos is entitled to severance as described in her Amended and Restated Employment Agreement dated October 16, 2024.
- Future Nominations: The Company agreed to nominate Christopher Martin for re-election at the 2026 and 2027 annual meetings until Frazier Life Sciences owns less than 5% of outstanding common stock.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated May 12, 2026) for specific Q1 2026 financial results, as they are not detailed in this 8-K text.
- Verify the terms of the Private Placement with Frazier Life Sciences to understand the context of the board seat designation.
- Confirm the specific severance amount for the departing Chief Commercial Officer by referencing the employment agreement filed in the 2025 Form 10-K.
- Monitor the June 8, 2026 effective date for the transition of the Board Chair role.